Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
Become a Member | Sign in
Home>News>This Article

BBSRC is Major Partner in Europe-wide Synthetic Biology Funding

Published: Tuesday, May 14, 2013
Last Updated: Tuesday, May 14, 2013
Bookmark and Share
BBSRC is contributing €3M as a major partner in a new call for research projects in Synthetic Biology.

The call is the first from the Synthetic Biology ERA-NET (ERASynBio) - a project designed to enhance European Synthetic Biology research through joint policy making, community building and training, and transnational funding.

BBSRC, along with 12 other ERASynBio funding agencies from Europe and the USA will support around €15M of research into this emerging field. The call represents a unique opportunity to build global Synthetic Biology capacity through innovative transnational projects.

The funding will allow European and US researchers to come together to work on high impact, high reward projects and address Synthetic Biology challenges which cannot be tackled at a national level.

Douglas Kell, BBSRC Chief Executive, said: "Synthetic biology has the potential to address some of the major challenges of the 21st Century as well as offering innovations to benefit the economy. By applying engineering principles to biological research we have the potential to shape the future of industrial compounds, biofuels and new medicines, and to provide exciting insights into fundamental biological mechanisms."

BBSRC's major involvement in this first funding call from ERASynBio highlights commitment and progress towards the UK building its leading international role in Synthetic Biology, as recommended in "A Synthetic Biology Roadmap for the UK" published in 2012.

Lionel Clarke of Shell Projects and Technology, who chaired the coordinating group for the roadmap, said: "International collaboration is essential to enhance research opportunities and make meaningful progress in this area. BBSRC's major involvement in this European project highlights the UK as a centre of international excellence taking a leading role in synthetic biology research.

ERASynBio describes Synthetic Biology as the engineering of biology: the deliberate (re)design and construction of novel biological and biologically based systems to perform new functions for useful purposes, that draws on principles elucidated from biology and engineering.

In the near future, Synthetic Biology could open doors to a more efficient processing and non-polluting manufacturing of fine chemicals and pharmaceuticals, and new routes for the generation of biofuels. However the long term potential of this emerging field can only be realised through strategic international cooperation.

ERASynBio welcomes multidisciplinary research proposals from a range of scientific areas including: metabolic engineering; regulatory circuits; orthogonal biosystems; bionanoscience; minimal genomes; protocells.

These applications have the potential to contribute to sectors including: industrial biotechnology, bioenergy, biomedicine, biosensors, bioremediation, agriculture and new tools for scientific research.

The new funding will provide an evolving line of European transnational projects and facilitate the identification of barriers in Synthetic Biology.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

New Way to Improve Antibiotic Production
A discovery has been made which could make it easier to scale up antibiotic production for commercialisation.
Tuesday, June 18, 2013
H7N9: A Novel Influenza Virus and it’s Control
Whilst the virus remains as one primarily circulating in birds, breaking this cycle of replication is the only effective response to its control.
Thursday, May 09, 2013
BBSRC Supports Call for Multi-Disciplinary Research Centres in Synthetic Biology
Up to six centres will be funded in two phases; three in this financial year and three next financial year.
Friday, May 03, 2013
Vaccine Production in Plants Nets Scientist Innovator of the Year 2012
Innovation could allow quicker vaccine development to combat pandemics.
Friday, March 30, 2012
Scientific News
"Good" Mozzie Virus Might Hold Key to Fighting Human Disease
Australian scientists have discovered a new virus carried by one of the country’s most common pest mosquitoes.
World’s First Therapeutic Venom Database
Open-source library describes nearly 43,000 effects on the human body.
Speeding Up the Process of Making Vaccines
System uses a freeze-dry concept to develop "just-add-water" solution.
Surprising Trait Found in Anti-HIV Antibodies
Scientists at The Scripps Research Institute (TSRI) have new weapons in the fight against HIV.
New Method Identifies Up to Twice as Many Proteins and Peptides
An international team of researchers developed a method that identifies up to twice as many proteins and peptides in mass spectrometry data than conventional approaches.
The Do’s and Don’ts of SPR Experiments
Surface Plasmon Resonance (SPR) is a technique that is becoming more widely used, particularly by anyone who wants to obtain accurate on (association) and off (dissociation) rates for biomolecular binding.
Genetically Engineering Algae to Kill Cancer Cells
New interdisciplinary research has revealed the frontline role tiny algae could play in the battle against cancer, through the innovative use of nanotechnology.
Novel Stem Cell Line Avoids Risk of Introducing Transplanted Tumors
Progenitor cells might eventually be used to repair or rebuild damaged or destroyed organs.
Single Vaccine for Chikungunya, Related Viruses May be Possible
What if a single vaccine could protect people from infection by many different viruses? That concept is a step closer to reality.
Blocking the Transmission Of Malaria Parasites
Vaccine candidate administered for the first time in humans in a phase I clinical trial led by Oxford University’s Jenner Institute, with partners Imaxio and GSK.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos